KOREA WHO
-
-
-
CEO of SK Biopharmaceuticals
Lee Dong-hoon
From Investment Expert to Bio CEO, Rich in Humanities
-
Last Updated on Jul 3, 2024
-
CEO of SK Biopharmaceuticals
Life Summary
Lee Dong-hoon is the President and CEO of SK Biopharmaceuticals. He also serves as the CEO of its subsidiaries, SK Life Science and SK Life Science Lab.
He is working on expanding the sales of the new epilepsy treatment drug 'Cenobamate' while also focusing on discovering new drug candidates and fostering the digital healthcare business.
He was born on August 12, 1968.
He graduated from the Department of Business Administration at Seoul National University and the Ohio State University Graduate School of Business in the United States.
After working at Samsung KPMG and Dong-A Socio Holdings, he joined the SK Group, where he was in charge of investments and mergers and acquisitions related to the bio business. He was involved in establishing a joint venture with Roivant in the United States and investing in the cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) company Iposkesi and CBM.
In 2022, he was appointed President of SK Biopharmaceuticals.
He is an investment expert with a notable humanities background.
He is also committed to disseminating economic knowledge to the general public.
#LeeDonghoon #SKBiopharmaceuticals #Cenobamate #digitalhealthcare #investment #biotech #SKGroup #OhioStateUniversity #SeoulNationalUniversity #economiceducation
He is working on expanding the sales of the new epilepsy treatment drug 'Cenobamate' while also focusing on discovering new drug candidates and fostering the digital healthcare business.
He was born on August 12, 1968.
He graduated from the Department of Business Administration at Seoul National University and the Ohio State University Graduate School of Business in the United States.
After working at Samsung KPMG and Dong-A Socio Holdings, he joined the SK Group, where he was in charge of investments and mergers and acquisitions related to the bio business. He was involved in establishing a joint venture with Roivant in the United States and investing in the cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) company Iposkesi and CBM.
In 2022, he was appointed President of SK Biopharmaceuticals.
He is an investment expert with a notable humanities background.
He is also committed to disseminating economic knowledge to the general public.
#LeeDonghoon #SKBiopharmaceuticals #Cenobamate #digitalhealthcare #investment #biotech #SKGroup #OhioStateUniversity #SeoulNationalUniversity #economiceducation